Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047019 | 0.77 | CYP11B1 (0.49) | NISCHCA12CYP1A2ALDH1A1 | |
| SCHEMBL32667946 | 0.75 | PDGFRB (0.77) | NISCHPDGFRBPDGFRACYP2A6BIRC5 | |
| SCHEMBL2772360 | 0.75 | PDGFRB (0.77) | NISCHPDGFRBPDGFRACYP2A6BIRC5 | |
| SCHEMBL4045625 | 0.72 | TOP2A (0.50) | NISCHPDGFRBPDGFRACYP2A6BIRC5 | |
| SCHEMBL69802 | 0.72 | SCN4A (0.45) | ALDH1A1 | |
| SCHEMBL714450 | 0.71 | PDGFRB (0.66) | NISCHPDGFRBPDGFRACYP2A6BIRC5 | |
| SCHEMBL5423443 | 0.71 | NPC1 (0.58) | NISCHPDGFRBPDGFRACYP2A6BIRC5 | |
| SCHEMBL4049958 | 0.71 | CYP1A2 (0.46) | CYP2A6CYP1A2 | |
| SCHEMBL4044619 | 0.71 | MKNK1 (0.41) | MKNK2 | |
| SCHEMBL6600638 | 0.71 | HPGDS (0.63) | NISCHPDGFRBPDGFRACYP2A6BIRC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| CN-102014900-B | Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist | UNIV HEALTH NETWORK | 2014-04-02 | — | — | CN | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| CN-102014900-A | Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist | UNIV HEALTH NETWORK | 2011-04-13 | — | — | CN | disclosed |
| EP-2262499-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | University Health Network (CA) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111868-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-17 | — | — | WO | disclosed |
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| CN-100457757-C | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2009-02-04 | — | — | CN | disclosed |
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | MSD K.K. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| CN-1370168-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2002-09-18 | — | — | CN | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | NPY1R, GPR119, NPY2R | NISCH 442/4885PDGFRB 711/4885PDGFRA 489/4885 |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | NISCH 3537/4885PDGFRB 274/4885PDGFRA 242/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | NISCH 177/4885PDGFRB 958/4885PDGFRA 1038/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | NISCH 4059/4885PDGFRB 550/4885PDGFRA 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.